Global analytical science and device company Trajan Group Holdings has reported headwinds across the board in its international business, but the strength of its products and a price rise puts the company on track to achieve a 40 per cent increase in sales this year.
Trajan, which operates seven manufacturing sites across the US, Australia, Europe and Penang, Malaysia, told investors it confirmed previous FY22 guidance of between $104 million and $110 million for the full year, 40 per cent up on the previous year.
Trajan said: “In any environment this is a strong result and indicative of the continued demand for our products and our global opportunities.”
However Trajan said it expected that global supply chain delays would hit the supply of its capital equipment products, with $1.7 million in revenue now re-timed to FY23.
However the company’s global capital equipment order book is at an all time high, and on June 1 introduced price increases which have been met ‘constructively’ by customers.
The company also expects an estimated devaluation of its future AUD/USD hedging contracts of $800,000.
The Ringwood, Victoria company said these two events had a combined effect on operating profit of $1.6 million, and so revised down its more than $12.5 million guidance for normalised EBITDA to more than $11.2 million.
“We are not immune to the increased pressures that are impacting many businesses; increases in materials costs, delayed supply chains, increased freight costs, the Ukraine conflict and Covid related absenteeism are all factors influencing our business today.”
Since its $50 million IPO in 2021 Trajan has been on an acquisition path, buying related companies Neoteryx, LEAP PAL Parts and Consumables, Axel Semrau and the MyHealth Test blood testing service.
Picture: Trajan/hemaPEN microsampling tool
Subscribe to our free @AuManufacturing newsletter here.